Vertex Pharmaceuticals Incorporated (VRTX)

148.54 -2.83 (-1.87%) At close: 4:00PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617-341-6100
http://www.vrtx.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 2,150

Key Executives

Name	Title	Pay	Exercised	Age
Dr. Jeffrey M. Leiden M.D., Ph.D.	Chairman, Chief Exec. Officer and Pres	3.56M	N/A	61
Mr. Ian F. Smith CPA, ACA	Chief Financial Officer, Chief Operating Officer and Exec. VP	1.33M	N/A	51
Dr. David M. Altshuler M.D., Ph.D.	Chief Scientific Officer and Exec. VP of Global Research	1.07M	N/A	52
Mr. Michael J. Parini J.D.	Chief Legal & Admin. Officer and Exec. VP	1.31M	N/A	42
Mr. Amit K. Sachdev J.D.	Chief Regulatory Officer, Chief of Staff to the Chief Exec. Officer and Exec. VP	979.72k	N/A	49

Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate Governance

Vertex Pharmaceuticals Incorporated’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.